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Abstract
Background: We aimed to identify predictors of anamnestic hypoglycaemia in type-2 diabetic patients on oral
mono- or dual oral combination antidiabetic pharmacotherapy.
Methods: DiaRegis is a prospective registry in type-2 diabetic patients in primary care. Odds ratios (OR) with 95%
confidence intervals were determined from univariate logistic regression. Using multivariate logistic regression
analysis with stepwise backward selection at an alpha of 0.05 independent predictors of hypoglycaemia were
determined.
Results: 3,808 patients had data on hypoglycaemia available (median age 65.9 years, 46.6% female). 10.8% had at
least one anamnestic hypoglycaemic episode within the previous 12 months. Patients with hypoglycaemia
received more sulfonylureas (OR 2.16; 95%CI 1.75-2.67) and less metformin (OR 0.64; 95%CI 0.50-0.82). On top of
metformin, patients with thiazolidine (OR 0.50; 95%CI 0.28-0.89) and DPP-4 inhibitor use (OR 0.34; 95%CI 0.16-0.70)
had a decreased risk for hypoglycaemia while it was again increased with sulfonylureas (OR 2.08; 95%CI 1.44-2.99).
Age < 65 years was an independent predictor of a reduced hypoglycaemia incidence (OR 0.76; 95%CI 0.59-0.96),
low HbA1c (OR 1.68; 95%CI 1.31-2.14), stroke/TIA (OR 1.72; 95%CI 1.08-2.72), heart failure (OR 1.77; 95%CI 1.28-2.45),
and the use of sulfonylureas (OR 2.58; 95%CI 2.03-3.29) were independent predictors of increased risk.
Conclusions: The results indicate that the risk of hypoglycaemia might be substantially reduced by carefully
selecting antidiabetic pharmacotherapy in patients with type-2 diabets in primary care.
Background
Hypoglycaemia is a serious and potentially life-threaten-
ing side effect of antidiabetic drug therapy. The inci-
dence depends on HbA1c targets [1-3] and the specific
drug or drug-drug combination prescribed [4]. Patients
on insulin are at particularly high risk for hypoglycaemia
compared to patients on oral antidiabetic drug therapy.
In the UKPDS the incidence of any hypoglycaemic event
in insulin-treated newly diagnosed type 2 diabetic
patients was 36.5 per 100 patient-years which was at
least twice as much as in sulfonylurea-treated patients
[5]. The incidence of severe hypoglycaemia was 2.3 per
100 patient-years which was a four- to sixfold increase
compared with the sulfonylurea-treated group. This is
the more disturbing since sulfonylureas have been
shown to confer the highest risk of hypoglycaemia
among oral antidiabetic drugs.
Severe hypoglycaemia was considered responsible for
excess deaths in the ACCORD trial [6]. Nineteen of the
41 excess deaths from cardiovascular causes in the study
were attributed to “unexpected or presumed cardiovas-
cular disease,” which may plausibly be related to or may
have been precipitated by hypoglycaemia and misclassi-
fied as having a cardiovascular cause. Combination
therapies, such as a sulfonylurea with insulin, are known
to be associated with an increased risk for hypoglycae-
mia and appear to have been used routinely in this
study. This is consistent with a recent analysis of a large
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cohort study [7], which has shown that mortality is low-
est in patients with a HbA1c level of 7.5% and increased
below this levels, more so in patients on insulin than in
patients on oral antidiabetic therapy. Later analyses of
ACCORD however suggested that while symptomatic,
severe hypoglycaemia was associated with an increased
risk of death, it was not responsible for the difference
between intensive and standard therapy [8].
Patients with type-2 diabetes who do not meet treat-
ment targets while receiving oral mono- or dual oral
combination therapy are at an increased risk for diabetes
and treatment related complications. To identify predic-
tors of incident hypoglycaemia in this patient population
we analyzed the dataset of the cross-sectional part of the
Diabetes Treatment Patterns and Goal Achievement in
Primary Diabetes Care (DiaRegis) Registry.
Methods
DiaRegis is a prospective, observational, German, multi-
center registry. The study protocol and baseline charac-
teristics of the patient population have been published
[9,10]. This registry is conducted in accordance with
Good Epidemiology Practices (GEP), and applicable reg-
ulatory requirements. The protocol of this registry was
approved by the ethics committee of the Landesärzte-
kammer Thüringen in Jena, Germany on March 4th
2009. Patients being enrolled into this registry provided
written informed consent. It was registered with the
database of the Verband forschender Arzneimittelherstel-
ler (VFA).
Patients
Between June 2009 and March 2010 patients with type-2
diabetes aged ≥ 40 years on oral mono or dual oral
combination antidiabetic therapy (no injectables such as
insulin and GLP-1 analogs) were included in which the
treating physician indicated a change of therapy to be
necessary. Patients not under regular supervision of the
treating physician for the duration of the study, those
with type-1 diabetes, pregnancy, diabetes secondary to
malnutrition, infection or surgery, with maturity onset
diabetes of the young, known cancer or limited life
expectancy, acute emergencies, participation in a clinical
trial and patients with further reasons that made it
impossible or highly problematic for the patient to parti-
cipate and come to the follow-up visits were excluded
from the registry.
Documentation
Patient characteristics at baseline were entered via a
secure website directly into an electronic database at the
Stiftung Institut für Herzinfarktforschung, Ludwigshafen,
Germany. At this stage they were automatically checked
for plausibility and completeness. Data from the patient
questionnaire (paper version) which was asked to be
completed by the patient during the visit were trans-
ferred to the responsible CRO Winicker Norimed
GmbH, Nürnberg, Germany. The questionnaires were
scanned and transferred to the Stiftung Institut für Her-
zinfarktforschung for evaluation.
Definition of endpoints (hypoglycaemia)
Hypoglycaemia was classified as follows. In case of
severe hypoglycaemia patients were seeking medical
attention or were admitted to hospital because of hypo-
glycaemia. In case of moderate hypoglycaemia patient
experienced symptoms of hypoglycaemia and required
assistance from a second person (e.g. a relative or
friend), but no attention of a medical professional was
necessary. Mild hypoglycaemia was determined from
blood glucose measurements (<2.22 mmol/l; 40 mg/dl in
any case; 2.22-2.78 or 50 mg/dl in case of symptoms)
and defined as being with or without specific symptoms
but manageable without foreign help.
For the present analysis all patients with valid infor-
mation regarding the presence or absence of hypogly-
caemic episodes during the last 12 months prior to
enrolment were included. These were obtained on an
anamnestic basis and multiple episodes with different
severities were possible to document.
Statistical analysis
The statistical analysis was performed using SAS, ver-
sion 9.1 (Cary, North Carolina, U.S.A.). The distribution
of metric variables is described with medians and quar-
tiles. All descriptive statistics are based on available
cases. Comparisons were made with the c2 or Mann-
Whitney-Wilcoxon Test. For patient characteristics
unadjusted odds ratios (OR) with 95%-confidence inter-
vals were determined from univariate analyses.
Stepwise multivariable logistic regression analysis was
used to estimate adjusted odds ratios (OR) with 95%
confidence intervals for the incidence of hypoglycaemia.
Variables entered into the multivariate model were iden-
tified from univariate analysis and included age, diabetes
duration, body mass index (BMI), waist circumference,
heart failure, depression, triglycerides, fasting and post-
prandial glucose as well as HbA1c.
Results
A total of 3,808 patients were available for the present
analysis. The incidence of hypoglycaemia of any type
and severity was 10.8% (n = 410). 89.2% (n = 3,398)
reported to have had no such episode. 48.8% of patients
with anamnestic hypoglycemia reported episodes with
no specific symptoms and 67.8% episodes with symp-
toms that were manageable without help (mild hypogly-
caemia). 8.3% had symptoms and required help
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(moderate hypoglycaemia). 3.1% were seeking attention
of a medical professional and 2.9% were admitted to the
hospital (severe hypoglycaemia).
Patient characteristics
Patients with hypoglycaemia were older (p < 0.001),
had a longer duration of diabetes (p < 0.01), a lower
body mass index (BMI; p < 0.0001) and waist circum-
ference (p < 0.001), and had lower triglyceride levels (p
< 0.001). HbA1c, fasting and postprandial glucose levels
were lower in patients with hypoglycaemia (p < 0.0001;
Table 1).
The prevalence of co-morbid (mostly) vascular disease
was similar between patients with or without hypogly-
caemia, except for coronary heart disease (OR 1.44; 95%
CI 1.13-1.85), prior stroke/TIA (OR 1.61; 95%CI 1.06-
2.44), heart failure (OR 1.99; 95%CI 1.42-2.66), amputa-
tion (OR 2.48; 95%CI 1.12-5.50), autonomous neuropa-
thy (OR 1.64; 95%CI 1.00-2.67) which were significantly
more frequent in patients with a history of hypoglycae-
mia (Table 2). Also clinically relevant depression was a
frequent observation with 11.7% of patients with a his-
tory of hypoglycaemia and 4.4% in patients without (OR
2.87; 95%CI 2.02-4.07).
Antidiabetic pharmacotherapy
Of all patients 84.0% received metformin, 28.8% sulfony-
lureas, 2.7% glucosidase inhibitors, 4.5% glinides, 6.3%
thiazolidinediones and 4.9% DPP-4 inhibitors. The use
of insulin or GLP-1 analogs was not permitted as to the
exclusion criteria. 68.6% received monotherapy and
31.4% dual combination therapy.
Patients having experienced hypoglycaemia received
monotherapy less (OR 0.72; 95%CI 0.58-0.89) and dual
oral combination therapy more frequently (OR 1.39;
95%CI 1.13-1.72) (Figure 1, upper panel). With respect
to single components metformin was used significantly
less (OR 0.64; 95%CI 0.50-0.82) in patients with hypo-
glycaemia while the use of sulfonylureas was increased
(OR 2.16; 95%CI 1.75-2.67). Further there was a strong
trend for a reduced hypoglycaemia incidence with gluco-
sidase inhibitors (OR 0.41; 95%CI 0.17-1.02), which was
non-significant (low patient numbers).
Figure 1, lower panel illustrates that patients report-
ing hypoglycaemia had frequently received a combina-
tion of sulfonylureas with metformin (OR 2.08; 95%CI
1.44-2.99). On the other hand patients receiving DPP-4
inhibitors (OR 0.34; 95%CI 0.16-0.70), thiazolidinediones
(OR 0.50; 95%CI 0.28-0.89) and as a trend glucosidase
inhibitors (OR 0.22; 95%CI 0.03-1.60) on top of metfor-
min had a decreased risk for hypoglycaemia in univari-
ate analyses.
Treatment decisions in patients with hypoglycaemia
In 74.4% of patients that had experienced hypoglycaemia
the therapy was changed because of suboptimal blood
glucose adjustments (OR 0.38; 95%CI 0.30-0.48 vs. no
hypoglycaemia), 30.7% because of hypoglycaemia (OR
187.8; 95%CI 90.99-387.8), 15.4% because of weight gain
(no difference), 10.5% due to unexpected adverse events
(OR 2.00; 95%CI 1.41-2.83) and a further 11.1% for a
variety of other reasons (no difference).
Compared to baseline the use of sulfonylureas in
patients with hypoglycaemia was strongly reduced
(-25.9%), while in a significant proportion of patients
DPP-4 inhibitors (+26.8%), GLP-1 analogs (+7.6%) and
insulins (+26.6%) were introduced (Figure 2). Surpris-
ingly there was a significantly higher degree of insulin
use in patients with anamnestic hypoglycaemia (OR
1.88; 95%CI 1.49-2.39), while less oral antidiabetic drugs
were prescribed in these patients (mean 1.5 ± 0.7 vs. 1.8
± 0.7; p < 0.0001).
Table 1 Patient characteristics and laboratory values at baseline
With hypoglycaemia (n = 410) %/median
(quartile)
Without hypoglycaemia (n = 3,398) %/median
(quartile)
p-value*
Age (years) 68.6 (59.0-74.7) 65.7 (57.5-72.7) <0.001
Women (%) 48.3 46.4 n.s.
Diabetes duration (years) 6.5 (3.3-10.4) 5.5 (2.8-9.2) <0.01
BMI (kg/m2) 29.0 (26.0-33.0) 30.5 (27.0-35.0) <0.0001
Waist circumference (cm) 104 (95-115) 107 (98-116) <0.001
Total cholesterol (mg/dl) 204 (174-231) 205 (177-232) n.s.
HDL-Cholesterol (mg/dl) 48 (41-59) 47 (40-56) n.s.
LDL-Cholesterol (mg/dl) 118 (95-145) 120 (98-145) n.s.
Triglycerides (mg/dl) 158 (116-216) 178 (129-246) <0.001
HbA1c (mg/dl) 7.2 (6.5-8.0) 7.4 (6.9-8.3) <0.0001
Fasting plasma glucose (mg/dl) 134 (111-162) 143 (121-173) <0.0001
Postprandial plasma
glucose (mg/dl)
172 (145-207) 186 (157-223) <0.0001
BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; HbA1c, glycosylated haemoglobin A1c; * c
2 or Mann-Whitney-Wilcoxon Test.
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Multivariable predictors of hypoglycaemia
Using logistic regression analysis we determined that an
age < 65 years (but not gender) was associated with a
reduced hypoglycaemia incidence (OR 0.76; 95%CI 0.59-
0.96). On the contrary anamnestic a low HbA1c (OR
1.68; 95%CI 1.31-2.14), stroke/TIA (OR 1.72; 95%CI
1.08-2.72), heart failure (OR 1.77; 95%CI 1.28-2.45), and
the use of sulfonylureas (OR 2.58; 95%CI 2.03-3.29)
were associated with an increased risk for
hypoglycaemia.
Table 2 Concomitant risk factors and disease
With hypoglycaemia (n = 398), % Without hypoglycaemia (n = 3,482), % OR (95%CI)*
Dyslipidemia (%) 60.0 63.7 0.86 (0.69-1.06)
Hypertension (%) 84.6 84.4 1.02 (0.77-1.35)
Coronary heart disease (%) 23.2 17.3 1.44 (1.13-1.85)
Prior stroke/TIA (%) 6.8 4.4 1.61 (1.06-2.44)
Heart failure (%) 16.6 9.1 1.99 (1.49-2.66)
PAD (%) 7.7 5.8 1.36 (0.92-2.02)
Amputation (%) 2.0 0.8 2.48 (1.12-5.50)
Autonomous neuropathy (%) 5.1 3.2 1.64 (1.00-2.67)
Peripheral neuropathy (%) 15.1 14.2 1.07 (0.80-1.43)
Non-prolif. retinopathy (%) 5.5 3.5 1.58 (0.99-2.52)
Proliferative retinopathy (%) 1.0 0.5 2.22 (0.73-6.71)
Blindness (%) 0 0.1 n.a.
Clinically rel. depression (%) 12.0 4.6 2.84 (2.02-4.01)
TIA, transitory ischemic attack; PAD, peripheral arterial disease; n.a., not applicable; OR, odds ratio; CI, confidence interval; *unadjusted.
Figure 1 Antidiabetic pharmacotherapy at baseline overall (upper panel) and metformin based dual combination therapy in patients
with and without hypoglycaemia in the past 12 months (lower panel). OAD, oral antidiabetic therapy; DPP-4, dipeptidyl peptidase-4; OR,
odds ratio; CI, confidence interval.
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Discussion
The treatment algorithm of the German Diabetes
Society (Deutsche Diabetes Gesellschaft, DDG) is based
on the achievement of HbA1c target levels [11]. When
metformin monotherapy is not sufficient because HbA1c
remains ≥ 6.5% but is < 7.5% after 3-6 month, a number
of different oral antidiabetic drugs are recommended to
be added. Insulin is recommended if HbA1c is still ≥
6.5% after further 3-6 month or if HbA1c is ≥ 7.5% after
the initial metformin monotherapy phase. This recom-
mendation is somewhat in contrast with the recommen-
dations of the American Diabetes Association (ADA)
which recommends to escalate metformin monotherapy
if HbA1c is 7% or higher and recommends to use sulfo-
nylureas (other than glibenclamide or chlorpropamide)
or a basal insulin because they are “well-validated core
therapies” [12]. As to these guidelines the use of further
oral antidiabetic drugs (pioglitazone, exenatide) may be
considered when hypoglycaemia is particularly undesir-
able (e.g. in patients who have hazardous jobs). Their
future use is however questionable because of their
recent withdrawal in parts of Europe [13]. The remain-
ing drug classes (glinides, glucosidase inhibitors, and
DPP-4 inhibitors) get only cursory mention in the ADA
guidelines. Finally the EASD guidance is less specific in
guiding escalation therapy, but states that metformin
usually is the treatment option of choice for both
mono- and combination therapy, including insulin [14].
The choice of drugs is based on the glucometabolic
situation and co-morbid disease conditions.
Pharmacotherapy and the risk of hypoglycaemia
The ADA guidelines emphasize the prevention of hypo-
glycaemia to be critical to the treatment strategy in type
2 diabetes [15]. A drug’s rate of hypoglycaemia is there-
fore to be considered when selecting a drug for treat-
ment. Within this context not only complications of
severe hypoglycaemia such as coma, cardiac arrhyth-
mias, or myocardial ischemia deserve mentioning but
also the symptoms and long term consequences of mild
hypoglycaemia [16]. In placebo controlled studies,
patients receiving sulfonylureas or glinides experienced
increased rates of hypoglycaemia (RR range, 4.57-7.50)
[4]. This was also confirmed in a recent meta-analysis,
which reported the incidence of overall hypoglycaemia
to be increased when glinides were added to a maxi-
mum tolerated dose of metformin (RR 7.92 (95%CI
1.45-43.21), while the risk with sulfonylureas was also
elevated but this was not significantly significant (RR
2.63; 95%CI 0.76-9.13) [4]. This increased risk is likely
because of an increase in insulin release, which may
occur independent of the presence of a glucose load
[17]. On the other hand there was a trend for a reduced
incidence of hypoglycaemia in the aforementioned
meta-analysis, the reduction not reaching significance
with a-glucosidase inhibitors (RR 0.60; 95%CI 0.08-
4.56), and DPP-4 inhibitors (RR 0.67; 95%CI 0.30-1.50).
The present analysis of the association between the
incidence of hypoglycaemia and different drug treatment
options confirms these prior findings and documents
that the differences observed in clinical trials are highly
Figure 2 Antidiabetic pharmacotherapy in patients with hypoglycemia within the last 12 months prior to enrolment and after therapy
change. DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; n.s., not significant; p-values calculated by the McNemar’s Test.
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relevant for clinical practice. Use of sulfonylureas was
associated with an increased hypoglycaemia incidence in
mono- (OR 1.98; 95% 1.45-2.75) as well as in combina-
tion therapy with metformin (OR 2.08; 95% 1.44-2.99),
which was even stronger after multiple adjustments for
significant differences in patient characteristics at base-
line (2.58; 95%CI 2.03-3.29). At a mean overall hypogly-
caemia rate of 10.8% and a strongly increased risk with
sulfonylureas it appears surprising that 18.5% of patients
still receive this drug class after therapy change. While
the ADA recommends sulfonylureas as a preferred esca-
lation of metformin monotherapy, the likely reason for
its frequent use is not their mentioning in the DDG
guidelines but their preference in the German disease
management program diabetes, which calls for the use
of sulfonylureas. Two limitations of the present dataset
with respect to this important question deserve men-
tioning. First, we did only document drug classes used
but not single drugs. This would have been important in
view of the perceived differential risk which appears to
be higher with glibenclamide or chlorpropamide, but
lower with other second-generation sulfonylureas (glicla-
zide, glimepiride, glipizide etc.) [18,19]. Second no infor-
mation on the dose of drugs was obtained, which
compromises to differentiate whether low doses of sulfo-
nylureas would have been more favourable.
On the other hand we found that metformin use was
associated with a lower incidence of hypoglycaemia (OR
0.64; 95%CI 0.50-0.82), the use of glucosidase inhibitors
showing a trend for a reduced incidence (OR 0.41; 95%
CI 0.17-1.02). DDP-4 inhibitors on top of metformin
were associated with a reduced incidence of hypoglycae-
mia (OR 0.34; 95%CI 0.16-0.70); as were thiazolidine-
dones (OR 0.50; 95%CI 0.28-0.89). Because of low
patients numbers (1.2% of patients) the strong trend for
glucosidase inhibitors (OR 0.22; 95%CI 0.03-1.60) was
non-significant. This finding is of importance since met-
formin and DPP-4 inhibitors are related in that metfor-
min has an inhibiting effect on DPP-4 [20]. The benefits
of metformin are also supported by a more recent
Cochrane analysis [21] and its role as a first line treat-
ment in patients with diabetes is undisputed [11,12]
which is underlined by 84.0% of patients receiving met-
formin in DiaRegis. 4.9% of patients received DPP-4
inhibitors in the present analysis, with the majority in
combination with metformin. DPP-4 inhibitors are only
effective under conditions of hyperglycaemia and disap-
pear when blood glucose values fall below the normal
range. Therefore they have no intrinsic risk of hypogly-
caemia. Consequently a meta-analysis of 29 clinical stu-
dies, severe hypoglycaemia (defined as hypoglycaemia
requiring external assistance) was reported for only 2
patients [22]. This is reassuring, given that in contrast
to sulfonylureas DPP-IV inhibitors have been available
for about 2 years now and are thus considered to be
relatively new. Likewise reduced rates of hypoglycaemia
have been reported of glucosidase inhibitors [4]. These
reports are however frequently only reporting a trend
because patients numbers have been low in the consid-
ered trials. The risk of hypoglycaemia is however
increased in combination with sulfonylureas (DiaRegis
OR 3.39; 95%CI 1.01-11.40), and this is attributable to
the effect of sulfonylureas [11].
Adjustment of pharmacotherapy in patients with
hypoglycaemia
The majority of patients enrolled into DiaRegis were to
be changed with respect to drug therapy at baseline
because of insufficient diabetes control. In patients with
anamnestic hypoglycaemia within the last 12 months
prior to enrolment, in 30.7% therapy was altered because
of hypoglycaemia, the majority because of insufficient
blood glucose control (multiple answers possible). While
the use of sulfonylureas was strongly reduced after
change (18.5 vs. 44.4%), there was a strong preference to
introduce DPP-4 inhibitors (+26.8%), GLP-1 analogs
(+7.6%) or any insulin (+26.6%) (Figure 2). The reduced
prescription of sulfonylureas and the increased use of
DPP-4 inhibitors is reasonable given the rationale out-
lined above. The frequent addition of insulin (most likely
due its potent lowering of blood glucose) to the oral anti-
diabetic drug therapy regimen is however surprising
when only considering the risk of hypoglycaemia. For
these a higher incidence of hypoglycaemia has been
reported in comparison to oral antidiabetics [23]. How-
ever, given that in 74.4% of patients, blood glucose
adjustment was the main reason for changing therapy,
insulin use might be reasonable and is enforced by the
guidelines. In the DDG guidance insulin is added if
HbA1c is ≥ 6.5% after 3-6 month of mono or multiple oral
antidiabetic drug therapy or if HbA1c is ≥ 7.5% after met-
formin monotherapy [11]. The ADA recommends using
insulin (or sulfonylureas) directly if HbA1c is not reduced
below 7.0% in patients on metformin monotherapy [12].
Conclusions
DiaRegis illustrates that there is considerable proportion
of patients, experiencing episodes of hypoglycaemia dur-
ing antidiabetic treatment on mono- or dual oral combi-
nation therapy. The incidence is strongly associated to
higher age (≥ 65 years), a low HbA1c and heart failure,
prior stroke/TIA, but the strongest independent predic-
tor is the use of sulfonylureas. The results indicate that
the risk of hypoglycaemia might be substantially reduced
by properly selecting antidiabetic pharmacotherapy in a
primary care cohort of type-2 diabetic patients.
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